PharmaJet’s devices solve various problems: 1) Needle stick/re-use/pass along disease 2) Bringing new vaccines to market which do not work with needles 3) Patient compliance (5-18% more people participate in immunization) 4) Return on investment/savings for back to the user for each injection Delivering vaccines without a needle addresses a host of issues around needle stick, testing, treatment, liability, and reuse, which spreads up to 20 blood-borne pathogens, accounting for 33,800 new HIV infections, 1.7 M hepatitis B Infections and 315,000 hepatitis C infections annually. In addition, as many as 500 M used needles are added to trash dumps and landfills every year with 75 million potentially infected with blood borne illnesses. Of the 16 B annual needles used for injection globally, an estimated 6.7 B are re-used. While PharmaJet is a safe immunization solution, it is also pre-clinical and clinical vaccine development enabling solution. PharmaJet’s partners globally include large pharma, researchers, and NGO’s, spanning more than 60 collaborations across more than 100 vaccine and therapeutic candidate developments. The range of injectables includes existing vaccines with long histories, some pursuing reduced dose intradermal claims (e.g. Polio, Yellow Fever, Rabies, HPV) to stretch vaccine supply and save money, to novel vaccines under development (e.g. COVID-19) and other therapeutic uses (e.g. cancer, allergens, and antibodies). Post market surveillance survey’s taken during fall flu immunizations within corporate immunization settings have demonstrated that 95% of those who experienced PharmaJet would choose it again for their next flu shot and recommend it to friends and family. In the case of fractional dose intradermal injection of IPV (Polio), caregiver and patient preference has been 99%. Ease of use and hands-off training has also been demonstrated, during a campaign in Pakistan where 500,000 children were immunized in five days. In these settings, 10-18% more participation was observed, which was attributed to elimination of needles. 24% of adults and 63% of children avoid immunization because of needles, according to a study published in Vaccine Magazine. Because increased herd immunity via immunization compliance is directly linked to health of individuals and their communities, it also translates to maintaining a healthy economy. Engineered to eliminate waste, PharmaJet’s syringes provide verifiable fixed accurate dosing, and facilitates capturing extra doses out of the vials. In published field assessments for the Polio Eradication Initiative, conducted in Gambia and Pakistan, PharmaJet’s intradermal platform versus needle based delivery processed patients 2-3x faster, captured 20% more out of the vaccine vials, and had 50% less weight and waste. Because there are no sharps, elimination of this cost allows for further savings. Altogether, depending on the cost of the vaccine, and any amortized needle-stick testing/treatment/liability (standard in the US) PharmaJet tends to see a 10-50% savings for each immunization.
PharmaJet’s user-friendly, inexpensive device platforms provide a “needle-free” fluid injection into the body. They are able to compete with traditional needle-syringe delivery, which inherently poses costly needle-stick, re-use and pass-along disease issues. These “jet” injectors are optimized for fixed-dose vaccine immunizations, a 2.5+ B annual volume market, growing in perpetuity by the birth cohort (140m) and vaccines they receive, and by the addition of new vaccines and therapeutics to address new disease threats (e.g. infectious disease, like Zika; cancer therapeutic vaccines; virus’ like COVID-19). Unique in the field of jet injection, PharmaJet is the only commercially available technology with appropriate regulatory clearances for reaching all target tissues (0.5 mL for intramuscular/subcutaneous—called Stratis; 0.1 mL for intradermal—called Tropis). Designed to deliver fast, safe and comfortable injections accurately, it is a Class II medical device. With FDA CDRH device regulatory awards, and similar regulatory achievements in 42 other countries, PharmaJet’s Stratis device is the only WHO PQS (prequalified for purchase via UNICEF) jet injection technology. PharmaJet’s Tropis device has similar approvals, and global clinical claims of generating a superior immune response using a fractional dose, for the Global Polio Eradication Initiative. PharmaJet’s novel vaccine portfolio now spans more than 100 developments with more than 60 collaboration partners. This includes 20 candidates for a COVID-19 solution. In many cases, the needle-free injection helps enable nucleic acid vaccines and cancer therapeutics to achieve a several fold higher immune response than needles, and eliminates the need for electroporation. Now entering a significant revenue stage, the combination of scaled platforms, engineering know-how, customer and collaboration partnerships, and regulatory and clinical achievements continue to attract collaborations for other injectable medicines, including also a prefilled syringe development. PharmaJet’s devices are spring powered, customized to deliver a comfortable injections, and reach the target tissue. The reusable injector is warranted for 20,000 injection use. The disposable syringes auto-disable after each use, and can be filled with vaccine/medicine from vial packaging with a filling adaptor.